T0	Outcomes 26 91	health-related quality of life, pain, and skeletal-related events
T1	Outcomes 318 334	overall survival
T2	Outcomes 339 377	radiographic progression-free survival
T3	Outcomes 586 659	health-related quality of life (HRQoL), pain, and skeletal-related events
T4	Outcomes 841 846	HRQoL
T5	Outcomes 987 998	Pain status
T6	Outcomes 1066 1107	Brief Pain Inventory Short Form (BPI-SF).
T7	Outcomes 1112 1142	primary analysis of HRQoL data
T8	Outcomes 1265 1354	change from baseline, percentage improvement, and time to deterioration in HRQoL and pain
T9	Outcomes 1360 1412	proportion of patients with a skeletal-related event
T10	Outcomes 1418 1455	time to first skeletal-related event.
T11	Outcomes 1591 1616	Median treatment duration
T12	Outcomes 1762 1795	significant treatment differences
T13	Outcomes 1887 1929	endpoints and EQ-5D visual analogue scale.
T14	Outcomes 1930 1974	Median time to deterioration in FACT-P total
T15	Outcomes 2274 2296	improvements in FACT-P
T16	Outcomes 2334 2357	[23%] of 790), in EQ-5D
T17	Outcomes 2396 2421	[16%] of 623), and visual
T18	Outcomes 2471 2490	603; all p<0路0001).
T19	Outcomes 2491 2517	Median time to progression
T20	Outcomes 2664 2688	CI 0路53-0路74]; p<0路0001)
T21	Outcomes 3009 3038	placebo group had experienced
T22	Outcomes 3041 3079	skeletal-related event by data cutoff.
T23	Outcomes 3080 3100	Median time to first
T24	Outcomes 3296 3322	INTERPRETATION In addition
T25	Outcomes 3374 3456	enzalutamide significantly improves patient-related outcomes and delays occurrence